Phase 1 study of the safety and acceptability of 3% w/w SPL7013 gel (VivaGel) applied vaginally in sexually active young women
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Astodrimer (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Starpharma
- 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2009 Planned number of patients changed from 40 to 61 as reported by ClinicalTrials.gov.
- 18 Aug 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.